CXCR4/CXCL12-mediated leukemia/stromal interactions are known to contribute to chemoresistance in CML [45–47] and are greatly diminished if CXCL12 concentration or activity is reduced. This evidence concerns the gene CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive.